Business and Balance Sheet

What Herbalife Is

Herbalife sells nutrition products through 6.4 million independent members in 95 markets. Sales fell 14% from their 2021 peak and adjusted profitability fell 35% before both stabilised; separately, $1.9 billion of share repurchases at roughly $48 a share in 2020 and 2021 left negative book equity and $2.0 billion of debt. The shares are now a $1.3 billion stub inside a $2.8 billion enterprise. Growth returned in 2025 and accelerated in early 2026, but the recruitment end of the network is thinning again outside Asia.

Sources: 2025 net sales, adjusted EBITDA margin and net leverage from the June 2026 corporate overview [1]; market capitalisation derived from 103,669,416 shares outstanding at April 29 2026 [2] at the July 27 2026 closing price of $12.18 (company price feed).

What the company sells, and to whom

Herbalife makes powders, shakes, teas and supplements and sells none of them in a shop. Products go to independent members, who buy at a discount to suggested retail price and either consume them, resell them, or build a downline organisation that earns commissions on its own sales. As of December 31, 2025 the company sold 144 product types across 95 markets; weight management — meal-replacement shakes, protein drinks, teas — was 54.5% of net sales, targeted nutrition 30.0%, and energy/sports/fitness 12.2% [3].

The member base is not a sales force in the ordinary sense. Of roughly 6.4 million total members at end-2025, 3.1 million were "preferred members" — consumers who simply buy at a discount — and 2.3 million were distributors, with a further 0.2 million sales representatives and independent service providers in China [4]. The economically consequential layer is much smaller: about 602,700 members worldwide had reached "sales leader" status as of February 2025, down from 620,400 two years earlier [5]. Roughly 63,000 Nutrition Clubs — small member-run storefronts where customers buy single servings — are the physical face of the network, about 8,800 of them in the United States [6].

Geographically the business has rotated hard. Asia Pacific is now the largest region at $1,729.8 million of 2025 net sales, ahead of EMEA at $1,114.4 million and North America at $1,033.0 million; China, once a $629.5 million business in 2021, is $279.1 million [7].

Source: Historical Financial Summary, June 2026 corporate overview presentation [8].

Two regions carried the decline. North American net sales fell 27.7% between 2021 and 2025; China fell 55.7%. Asia Pacific grew 9.1% over the same span and Latin America 7.1%, which is why consolidated sales fell 13.2% rather than collapsing.

Where the money actually goes

Herbalife reports a 77.9% gross margin [9]. That number is not comparable to a packaged-food company's, because the cost of getting product to the consumer sits below the gross-profit line rather than in it. The distribution channel is paid out of "selling expenses": for 2025 the company applied, on a weighted-average basis, roughly 90% of suggested retail price as its billing base, gave discounts of up to 50% for distributor allowances, paid commissions and bonuses totalling up to 22% in aggregate, and allocated about 1% to a further bonus [10].

Stacked up, the economics of a dollar of net sales are stable and thin. Selling expenses — almost entirely member compensation — took 35.4% of sales in 2025, general and administrative costs 33.0%, and what fell through as adjusted EBITDA was 13.1% [11].

Source: Historical Financial Summary, June 2026 corporate overview presentation [12].

Member compensation held between 35% and 38% of sales across five years — that ratio is contractual and, in practice, close to fixed. Administrative costs rose from 28.6% of sales in 2021 to 34.6% in 2024 as revenue fell against a cost base built for a larger company, then came back to 33.0% in 2025. A restructuring programme begun in Q1 2024 and completed at end-2025 delivered roughly $80 million of annual savings for about $76.1 million of cumulative pre-tax cost [13]. That is most of the 2025 margin recovery.

The balance sheet the buybacks built

Herbalife carries negative book equity — a shareholders' deficit of $441.5 million at March 31, 2026 [14]. Share repurchases put it there: the 2020 and 2021 buybacks were recorded as an increase to shareholders' deficit rather than run through earnings [15]. The transaction detail, and what those shares are worth at today's price, is the opening of Pay and Capital Allocation. The company has bought no shares in the open market in 2023, 2024 or 2025 [16], and has paid no dividend since 2014 [17].

What the balance sheet inherited was debt. Scheduled principal at December 31, 2025 was $2,050.0 million, of which $1,710.3 million fell due in 2029, and interest expense for the year was $214.4 million [18]. Against $481.0 million of operating income [19], interest consumed 45 cents of every operating dollar. An April 2024 refinancing had cut borrowings but raised the weighted-average rate [20] — interest expense in 2023 had been $165.9 million [21].

That is the position a second refinancing, completed April 29, 2026, addressed. The stack it left is a Term Loan A, a drawn revolver and $800 million of 7.750% senior secured notes due 2033, and the company puts the annual cash interest saving at roughly $45 million [22]. The terms of that exchange, the covenant package attached to it and what it cost to get out of the old stack are the subject of Debt and Covenants.

Source: Capital Structure, June 2026 corporate overview presentation, maturities as of April 29 2026 [23].

Leverage stood at 2.7 times total and 2.1 times net at March 31, 2026 [24]. With $1,991.1 million of debt and $451.2 million of cash on the March balance sheet [25] and 103.7 million common shares outstanding as of April 29, 2026 [26] at $12.18, the equity is about $1.26 billion of a roughly $2.80 billion enterprise value — 45% of the capital structure. That build is struck on balance-sheet debt; Valuation Arithmetic runs the same ratio on Credit Agreement total debt, the larger of the two measures, and so carries a higher enterprise value and a lower equity share. Against the mid-point of 2026 adjusted EBITDA guidance of $675–705 million [27], that enterprise value is about 4.1 times.

What the shares have done

$100 invested in Herbalife at the end of 2020 was worth $26.83 at the end of 2025. The same $100 in the S&P 500 was worth $196.16, and in the company's chosen peer group $62.22 [28].

Source: Performance Graph, FY2025 Form 10-K, Item 5; comparators are the S&P 500 Index and the company's selected peer group [29].

The intra-period path is wider than the annual marks suggest. On the daily price series, the shares peaked at $61.47 in February 2019, closed at $5.11 on February 12, 2025, and closed at $12.18 on July 27, 2026 — roughly 2.4 times the low and 80% below the peak. Sell-side coverage is thin: consensus estimate data shows four contributing analysts, a 2026 EPS estimate of $2.56 rising to $3.15 for 2027, and a mean target of $18.33.

Where the business stands in mid-2026

2025 revenue grew for the first time since 2021, but the composition matters. Net sales rose 0.9% to $5,037.5 million on a 3.2% favourable price effect, a 1.6% currency drag and a 0.5% decline in sales volume, so the growth came from price rather than units [30].

The reported bottom line for 2025 understates what happened underneath it. Net income attributable to Herbalife fell 10.2% to $228.3 million, but operating income rose 24.7% to $481.0 million and pre-tax income rose 62.4% to $275.1 million [31]. The gap is tax: 2024 carried an $84.9 million income tax benefit, including a large deferred tax asset recognised on a fourth-quarter corporate reorganisation, giving an effective rate of negative 50.1% against 17.2% in 2025 [32]. Cash corroborates the operating direction rather than the EPS line: operating cash flow was $333.3 million against capital expenditure of $80.4 million, so free cash flow of $252.9 million exceeded net income by 11% and equalled about a fifth of the current market capitalisation [33].

The first quarter of 2026 was the first genuinely volume-led quarter in years. Net sales of $1,317.2 million were up 7.8%, and the bridge attributes $50.1 million to volume against $39.6 million to pricing, with $25.6 million of country-mix drag and $29.1 million of currency tailwind [34]. Management raised the floor of full-year guidance to net sales growth of 1.5–5.5% and adjusted EBITDA of $675–705 million against $657.6 million in 2025 [35].

The recruitment data underneath that quarter runs the other way, and it is the strongest fact against reading 2026 as a durable turn. Worldwide new distributor growth was negative 2% year on year in Q1 2026, with North America down 15%, EMEA down 22% and China down 21%; only Asia Pacific grew, at 18%. Recruiting activity fell at every sales-leader rank except the two lowest [36]. Regional net sales tell the same story: North America down 3% and China down 12% in the quarter, against Asia Pacific up 17% [37].

My read is that the operating recovery is real but narrow: cost reduction and pricing did the work through 2025, Asia Pacific did it in early 2026, and the network outside Asia has not resumed adding people. Two or three consecutive quarters of positive new-distributor growth in North America and EMEA, alongside volume-led sales growth, would make the case that the base has genuinely stabilised. A return to negative worldwide volume once the currency tailwind fades would not.

One disclosure limitation is worth registering at the outset. Herbalife disclosed Volume Points by geographic region for years — the cleanest available proxy for units moved through the network — and stopped: management concluded the metric had lost its usefulness and no longer publishes it [38]. Regional volume can now only be inferred from the sales bridges and the quarterly recruitment tables.

What this report sets out to answer

Whether Herbalife's return to growth reflects a distributor network that has genuinely stabilised, or price increases and currency covering a base that is still contracting — because with roughly $1.5 billion of net debt against a $1.3 billion market capitalisation, the equity is a leveraged claim on the answer.